EGFR and non-small cell lung carcinoma: In summary, this study underscores the efficacy of both Afatinib and Osimertinib as first-line therapies for EGFR-mutant NSCLC, with Osimertinib offering a longer ToT and Afatinib showing potential for extended OS with sequential second-line therapy.